98%
921
2 minutes
20
How human genetic variation contributes to vaccine effectiveness in infants is unclear, and data are limited on these relationships in populations with African ancestries. We undertook genetic analyses of vaccine antibody responses in infants from Uganda (n = 1391), Burkina Faso (n = 353) and South Africa (n = 755), identifying associations between human leukocyte antigen (HLA) and antibody response for five of eight tested antigens spanning pertussis, diphtheria and hepatitis B vaccines. In addition, through HLA typing 1,702 individuals from 11 populations of African ancestry derived predominantly from the 1000 Genomes Project, we constructed an imputation resource, fine-mapping class II HLA-DR and DQ associations explaining up to 10% of antibody response variance in our infant cohorts. We observed differences in the genetic architecture of pertussis antibody response between the cohorts with African ancestries and an independent cohort with European ancestry, but found no in silico evidence of differences in HLA peptide binding affinity or breadth. Using immune cell expression quantitative trait loci datasets derived from African-ancestry samples from the 1000 Genomes Project, we found evidence of differential HLA-DRB1 expression correlating with inferred protection from pertussis following vaccination. This work suggests that HLA-DRB1 expression may play a role in vaccine response and should be considered alongside peptide selection to improve vaccine design.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11108778 | PMC |
http://dx.doi.org/10.1038/s41591-024-02944-5 | DOI Listing |
Background: Ischemic stroke results in significant morbidity and mortality. By examining gene expression of cells comprising stroke clots, we aim to gain valuable insights into the underlying mechanisms of this disease and identify potential biomarkers of stroke cause.
Methods: We employed single-cell RNA sequencing to analyze 10 clot samples from patients diagnosed with large vessel occlusion stroke.
HLA
August 2025
Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, the Netherlands.
In pregnancy, semi-allogenic foetal trophoblasts express a specific HLA profile mediating maternal leukocyte contact, crucial for placentation. Paradoxically, maternal immunomodulation requires foetal antigen recognition, especially involving certain HLA molecules. Pre-eclampsia, a severe hypertensive complication, has been linked to antigenic similarity.
View Article and Find Full Text PDFHum Immunol
August 2025
Anthony Nolan Research Institute, Royal Free Hospital, London, UK; UCL Cancer Institute, Royal Free Campus, London, UK.
HLA compatibility between patients and donors is a determining factor for the success of stem cell and solid organ transplantations. However, finding suitable donors remains challenging due to the highly polymorphic nature of HLA genes. Here we are describing 16 novel HLA-A, -B, -C and -DRB1 alleles identified over the period of 2 years.
View Article and Find Full Text PDFJ Mol Neurosci
August 2025
Branch of Clinical Sciences, University of Sulaimani, College of Medicine, Sulaymaniyah, 46001, Iraq.
This is the first study in Iraq to integrate socioeconomic, genetic, and oxidative stress markers in MS patients, revealing unique associations between HLA-DRB1 polymorphisms and relapsing-remitting MS (RRMS). This work investigated the demographic, clinical, oxidative stress, and molecular aspects influencing quality of life in multiple sclerosis patients in Sulaymaniyah, Iraq. A cross-sectional study was undertaken with 63 MS patients and 20 healthy controls to evaluate quality of life using the Multiple Sclerosis Quality of Life-54 (MSQoL-54) questionnaire.
View Article and Find Full Text PDFMult Scler Relat Disord
July 2025
Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Parkville VIC 3050, Australia; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville VIC 3052, Australia.
Background: Mer tyrosine kinase (MERTK), is a regulator of immune activity. HLA-DRB1*1501 and MERTK are modulators of MERTK expression on monocytes, and risk genes for Multiple Sclerosis (MS). Natalizumab treatment inhibits lymphocyte but not monocyte ingress into the CNS.
View Article and Find Full Text PDF